OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections.

OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections.

Blog Article

Lantibiotics continue to offer an untapped pipeline for the development of novel antibiotics.We report here the discovery of a novel lantibiotic for the treatment of C.difficile infection (CDI).The leads were selected from Baby Formula a library of over 300 multiple substitution variants of the lantibiotic Mutacin 1140 (MU1140).

Top performers were selected based on testing for superior potency, solubility, manufacturability, and physicochemical and/or metabolic Stock Reins stability in biologically-relevant systems.The best performers in vitro were further evaluated orally in the Golden Syrian hamster model of CDAD.In vivo testing ultimately identified OG716 as the lead compound, which conferred 100% survival and no relapse at 3 weeks post infection.MU1140-derived variants are particularly attractive for further clinical development considering their novel mechanism of action.